• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 4/9/24: Is That AI Mammogram Worth the Cost? What Digital Technologies are Enhancing Trial Enrollment and Diversity? & more


The latest news for pharma industry insiders.

What Digital Technologies are Being Used to Enhance Clinical Trial Enrollment and Diversity?

Systematic review of research articles sought to identify and characterize different technologies being used in clinical studies.

Investment in digital health? Definitely. ROI? Maybe.

The imperative to upgrade healthcare technology infrastructure is clear, but the returns from such investment are anything but.

Is That AI Mammogram Worth the Cost?

The new add-on service for breast exams can cost between $40 and $100. We asked experts to separate the sales pitch from the science.

ViiV Healthcare announces U.S. FDA approval of Dovato(dolutegravir/lamivudine) for adolescents living with HIV

Dovato is now the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older living with HIV, a population in need of additional treatment options

Marie Teil on LinkedIn:

Thanks Miranda Schmalfuhs for the opportunity to share some of the challenges #women with #chronicillnesses face when accessing appropriate treatment and participating in clinical trials! This is also why we initiated BRIDGE (Better Research, Information and Data Generation for Empowerment) https://lnkd.in/ehd9AC8R

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs